Shih Alvin, a director at Zevra Therapeutics ($ZVRA), made one open market purchase of common shares in the last year, totaling about $158,000, with the most recent on September 12, 2025. This ranks him 1,764th among 4,983 individual insiders by purchase value, below the average of $1.5 million across 3.29 transactions per insider. He reported no open market sales in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sept. 12, 2025 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Shih Alvin | Director | P | Common Stock | 20000 | $7.89 | 20,000.0000 | 47,808,817 | 9999.99% | 0.04% |
| May 29, 2025 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Shih Alvin | Director | A | Stock Option (right to buy) | 30000 | $0.00 | 30,000.0000 | 47,808,817 | 9999.99% | 0.06% |
| May 13, 2024 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Shih Alvin | Director | A | Stock Option (right to buy) | 39200 | $0.00 | 39,200.0000 | 0 | 9999.99% | 0.00% |
| Jan. 20, 2024 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Shih Alvin | Director | A | Stock Option (right to buy) | 58800 | $0.00 | 58,800.0000 | 0 | 9999.99% | 0.00% |